Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,355 USD | -3,90% | +4,57% | +63,38% |
Omzet 2024 * | 30,5 mln. 28,28 mln. | Omzet 2025 * | 60,44 mln. 56,04 mln. | Marktkapitalisatie | 237 mln. 220 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -89 mln. -82,52 mln. | Nettowinst (verlies) 2025 * | -103 mln. -95,5 mln. | EV/omzet 2024 * | 7,76 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 3,92 x |
K/w-verhouding 2024 * |
-3,27
x | K/w-verhouding 2025 * |
-3,25
x | Werknemers | 93 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 97,06% |
Recentste transcriptie over X4 Pharmaceuticals, Inc.
1 dag | -2,76% | ||
1 week | +38,24% | ||
Lopende maand | +45,27% | ||
1 maand | +41,62% | ||
3 maanden | +62,89% | ||
6 maanden | +28,18% | ||
Lopend jaar | +68,16% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Paula Ragan
FOU | Founder | 54 | 01-01-10 |
Adam Mostafa
DFI | Director of Finance/CFO | 44 | 01-09-18 |
Mary DiBiase
COO | Chief Operating Officer | 63 | 01-01-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Michael Wyzga
CHM | Chairman | 69 | 01-07-18 |
David McGirr
BRD | Director/Board Member | 69 | 01-09-17 |
Paula Ragan
FOU | Founder | 54 | 01-01-10 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.00% | 36 M€ | +4,74% | - |
Datum | Koers | Variatie | Volume |
---|---|---|---|
28-03-24 | 1,355 | -3,90% | 604 549 |
27-03-24 | 1,41 | -2,76% | 2 153 911 |
26-03-24 | 1,45 | -0,68% | 3 076 383 |
25-03-24 | 1,46 | 0,00% | 6 542 159 |
22-03-24 | 1,46 | +11,45% | 12 734 428 |
uitgestelde koers Nasdaq, 27 maart 2024 om 21:00 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+68,16% | 237 mln. | |
+9,16% | 45,97 mld. | |
+53,80% | 43,93 mld. | |
+11,20% | 42,34 mld. | |
-8,59% | 28,27 mld. | |
+16,40% | 27,18 mld. | |
-19,34% | 19,44 mld. | |
+13,95% | 13,83 mld. | |
+31,56% | 12,4 mld. | |
+10,63% | 11,45 mld. |